Comparing two blood collection methods in men with metastatic prostate cancer
Compares two ways of collecting tumor cells from the blood in men with prostate cancer.
Plain-language title generated from the registry record
Registry title: A Trial to Evaluate the Effect of Applying Leukapheresis to Enrich CTCs in mPCa Patients
Key facts
- Where
- Shanghai, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06469710, who can take part
Where in China
- Renji Hospital, Shanghai Jiao Tong UniversityShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- RenJi Hospital
- Trial code
- NCT06469710
- Record updated
- 11 August 2026
- Original description
The goal of this observational study is to compare the number of CTCs enriched by both sampling methods, leukapheresis and collection of peripheral blood in metastatic prostate cancer patients. The main questions it aims to answer are:Read full original descriptionShow less
A Trial to Evaluate the Effect of Applying Leukapheresis to Enrich CTCs in Patients With Metastatic Prostate Cancer
The goal of this observational study is to compare the number of CTCs enriched by both sampling methods, leukapheresis and collection of peripheral blood in metastatic prostate cancer patients. The main questions it aims to answer are:
1. The advantages and disadvantages of two sampling methods for further diagnosis and treatment; 2. How to obtain further information on the tumour biology of CTC; 3. The mechanisms of prostate cancer invasion and metastasis Participants will have 7.5mL of peripheral blood taken as well as undergo leukapheresis.
Inclusion: male, aged 18-75 years; and; Evidence of metastasis (positive finding of metastasis on one of the following tests: CT and MRI; whole-body nuclear bone imaging, fluoride PET and PET-CT, cholinergic PET-CT and MRI; prostate-specific membrane antigen-targeted PET-CT); or clinical diagnosis of metastatic prostate cancer (tumour stage of T3 and above) by pathology of aspiration/surgical biopsy; Good general condition, ECOG score 0-1, able to tolerate leukapheresis; Normal haematological analysis, liver and renal function tests at screening; Subjects (or their legal representatives) can understand the informed consent form.
Exclusion: those who have received systemic combination therapy for tumours within 5 years; those receiving exogenous plasma at the time of the trial; those with poor general condition, severe haemodynamic instability, malignant arrhythmias, cachexia and infections; those with coagulation disorders, DIC or reduced platelets.